Terms: = Thyroid cancer AND PPARG, PPARG1, 5468, ENSG00000132170, PPARG2, NR1C3, HUMPPARG AND Prognosis
11 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics.
Dong X; Yang Y; Xu G; Tian Z; Yang Q; Gong Y; Wu G
Cancer Med; 2022 Mar; 11(5):1371-1395. PubMed ID: 35037412
[TBL] [Abstract] [Full Text] [Related]
3. Identification of hub genes in thyroid carcinoma to predict prognosis by integrated bioinformatics analysis.
Pan Y; Wu L; He S; Wu J; Wang T; Zang H
Bioengineered; 2021 Dec; 12(1):2928-2940. PubMed ID: 34167437
[TBL] [Abstract] [Full Text] [Related]
4. Visceral Metastasis: A Prognostic Factor of Survival in Patients with Spinal Metastases.
Lun DX; Chen NW; Feng JT; Yang XG; Xu ZW; Li F; Hu YC
Orthop Surg; 2020 Apr; 12(2):552-560. PubMed ID: 32227458
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
6. Molecular pathology and thyroid FNA.
Poller DN; Glaysher S
Cytopathology; 2017 Dec; 28(6):475-481. PubMed ID: 29165888
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Markers Involved in Tumorigenesis of thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract] [Full Text] [Related]
8. Genetics and epigenetics of sporadic thyroid cancer.
Vu-Phan D; Koenig RJ
Mol Cell Endocrinol; 2014 Apr; 386(1-2):55-66. PubMed ID: 23933154
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of the PAX8/pparg translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis.
Algeciras-Schimnich A; Milosevic D; McIver B; Flynn H; Reddi HV; Eberhardt NL; Grebe SK
Clin Chem; 2010 Mar; 56(3):391-8. PubMed ID: 20056739
[TBL] [Abstract] [Full Text] [Related]
10. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.
Pita JM; Banito A; Cavaco BM; Leite V
Br J Cancer; 2009 Nov; 101(10):1782-91. PubMed ID: 19809427
[TBL] [Abstract] [Full Text] [Related]
11. New trends in the treatment of undifferentiated carcinomas of the thyroid.
Miccoli P; Materazzi G; Antonelli A; Panicucci E; Frustaci G; Berti P
Langenbecks Arch Surg; 2007 Jul; 392(4):397-404. PubMed ID: 17131154
[TBL] [Abstract] [Full Text] [Related]